Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.
Identifieur interne : 002E36 ( PubMed/Corpus ); précédent : 002E35; suivant : 002E37Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.
Auteurs : Séverine Roselli ; Jay Pundavela ; Yohann Demont ; Sam Faulkner ; Sheridan Keene ; John Attia ; Chen Chen Jiang ; Xu Dong Zhang ; Marjorie M. Walker ; Hubert HondermarckSource :
- Oncotarget [ 1949-2553 ] ; 2015.
English descriptors
- KwdEn :
- Adaptor Proteins, Vesicular Transport (metabolism), Apoptosis (physiology), Biomarkers, Tumor (metabolism), Breast Neoplasms (metabolism), Breast Neoplasms (pathology), Carcinoma, Ductal, Breast (metabolism), Carcinoma, Ductal, Breast (pathology), Cell Adhesion (physiology), Cell Movement (physiology), Female, Humans, Immunohistochemistry, MCF-7 Cells, Middle Aged, Neoplasm Invasiveness, Transfection.
- MESH :
- chemical , metabolism : Adaptor Proteins, Vesicular Transport, Biomarkers, Tumor.
- metabolism : Breast Neoplasms, Carcinoma, Ductal, Breast.
- pathology : Breast Neoplasms, Carcinoma, Ductal, Breast.
- physiology : Apoptosis, Cell Adhesion, Cell Movement.
- Female, Humans, Immunohistochemistry, MCF-7 Cells, Middle Aged, Neoplasm Invasiveness, Transfection.
Abstract
The neuronal membrane protein sortilin has been reported in a few cancer cell lines, but its expression and impact in human tumors is unclear. In this study, sortilin was analyzed by immunohistochemistry in a series of 318 clinically annotated breast cancers and 53 normal breast tissues. Sortilin was detected in epithelial cells, with increased levels in cancers, as compared to normal tissues (p = 0.0088). It was found in 79% of invasive ductal carcinomas and 54% of invasive lobular carcinomas (p < 0.0001). There was an association between sortilin expression and lymph node involvement (p = 0.0093), suggesting a relationship with metastatic potential. In cell culture, sortilin levels were higher in cancer cell lines compared to non-tumorigenic breast epithelial cells and siRNA knockdown of sortilin inhibited cancer cell adhesion, while proliferation and apoptosis were not affected. Breast cancer cell migration and invasion were also inhibited by sortilin knockdown, with a decrease in focal adhesion kinase and SRC phosphorylation. In conclusion, sortilin participates in breast tumor aggressiveness and may constitute a new therapeutic target against tumor cell invasion.
DOI: 10.18632/oncotarget.3401
PubMed: 25871389
Links to Exploration step
pubmed:25871389Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.</title><author><name sortKey="Roselli, Severine" sort="Roselli, Severine" uniqKey="Roselli S" first="Séverine" last="Roselli">Séverine Roselli</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Pundavela, Jay" sort="Pundavela, Jay" uniqKey="Pundavela J" first="Jay" last="Pundavela">Jay Pundavela</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Demont, Yohann" sort="Demont, Yohann" uniqKey="Demont Y" first="Yohann" last="Demont">Yohann Demont</name><affiliation><nlm:affiliation>INSERM U908, IFR-147, Universite Lille 1, Villeneuve d'Ascq 59655, France.</nlm:affiliation></affiliation></author><author><name sortKey="Faulkner, Sam" sort="Faulkner, Sam" uniqKey="Faulkner S" first="Sam" last="Faulkner">Sam Faulkner</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Keene, Sheridan" sort="Keene, Sheridan" uniqKey="Keene S" first="Sheridan" last="Keene">Sheridan Keene</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Attia, John" sort="Attia, John" uniqKey="Attia J" first="John" last="Attia">John Attia</name><affiliation><nlm:affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Jiang, Chen Chen" sort="Jiang, Chen Chen" uniqKey="Jiang C" first="Chen Chen" last="Jiang">Chen Chen Jiang</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Xu Dong" sort="Zhang, Xu Dong" uniqKey="Zhang X" first="Xu Dong" last="Zhang">Xu Dong Zhang</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Walker, Marjorie M" sort="Walker, Marjorie M" uniqKey="Walker M" first="Marjorie M" last="Walker">Marjorie M. Walker</name><affiliation><nlm:affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hondermarck, Hubert" sort="Hondermarck, Hubert" uniqKey="Hondermarck H" first="Hubert" last="Hondermarck">Hubert Hondermarck</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25871389</idno><idno type="pmid">25871389</idno><idno type="doi">10.18632/oncotarget.3401</idno><idno type="wicri:Area/PubMed/Corpus">002E36</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.</title><author><name sortKey="Roselli, Severine" sort="Roselli, Severine" uniqKey="Roselli S" first="Séverine" last="Roselli">Séverine Roselli</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Pundavela, Jay" sort="Pundavela, Jay" uniqKey="Pundavela J" first="Jay" last="Pundavela">Jay Pundavela</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Demont, Yohann" sort="Demont, Yohann" uniqKey="Demont Y" first="Yohann" last="Demont">Yohann Demont</name><affiliation><nlm:affiliation>INSERM U908, IFR-147, Universite Lille 1, Villeneuve d'Ascq 59655, France.</nlm:affiliation></affiliation></author><author><name sortKey="Faulkner, Sam" sort="Faulkner, Sam" uniqKey="Faulkner S" first="Sam" last="Faulkner">Sam Faulkner</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Keene, Sheridan" sort="Keene, Sheridan" uniqKey="Keene S" first="Sheridan" last="Keene">Sheridan Keene</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Attia, John" sort="Attia, John" uniqKey="Attia J" first="John" last="Attia">John Attia</name><affiliation><nlm:affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Jiang, Chen Chen" sort="Jiang, Chen Chen" uniqKey="Jiang C" first="Chen Chen" last="Jiang">Chen Chen Jiang</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Xu Dong" sort="Zhang, Xu Dong" uniqKey="Zhang X" first="Xu Dong" last="Zhang">Xu Dong Zhang</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Walker, Marjorie M" sort="Walker, Marjorie M" uniqKey="Walker M" first="Marjorie M" last="Walker">Marjorie M. Walker</name><affiliation><nlm:affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hondermarck, Hubert" sort="Hondermarck, Hubert" uniqKey="Hondermarck H" first="Hubert" last="Hondermarck">Hubert Hondermarck</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Oncotarget</title><idno type="eISSN">1949-2553</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptor Proteins, Vesicular Transport (metabolism)</term><term>Apoptosis (physiology)</term><term>Biomarkers, Tumor (metabolism)</term><term>Breast Neoplasms (metabolism)</term><term>Breast Neoplasms (pathology)</term><term>Carcinoma, Ductal, Breast (metabolism)</term><term>Carcinoma, Ductal, Breast (pathology)</term><term>Cell Adhesion (physiology)</term><term>Cell Movement (physiology)</term><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>MCF-7 Cells</term><term>Middle Aged</term><term>Neoplasm Invasiveness</term><term>Transfection</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adaptor Proteins, Vesicular Transport</term><term>Biomarkers, Tumor</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Apoptosis</term><term>Cell Adhesion</term><term>Cell Movement</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>MCF-7 Cells</term><term>Middle Aged</term><term>Neoplasm Invasiveness</term><term>Transfection</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The neuronal membrane protein sortilin has been reported in a few cancer cell lines, but its expression and impact in human tumors is unclear. In this study, sortilin was analyzed by immunohistochemistry in a series of 318 clinically annotated breast cancers and 53 normal breast tissues. Sortilin was detected in epithelial cells, with increased levels in cancers, as compared to normal tissues (p = 0.0088). It was found in 79% of invasive ductal carcinomas and 54% of invasive lobular carcinomas (p < 0.0001). There was an association between sortilin expression and lymph node involvement (p = 0.0093), suggesting a relationship with metastatic potential. In cell culture, sortilin levels were higher in cancer cell lines compared to non-tumorigenic breast epithelial cells and siRNA knockdown of sortilin inhibited cancer cell adhesion, while proliferation and apoptosis were not affected. Breast cancer cell migration and invasion were also inhibited by sortilin knockdown, with a decrease in focal adhesion kinase and SRC phosphorylation. In conclusion, sortilin participates in breast tumor aggressiveness and may constitute a new therapeutic target against tumor cell invasion.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25871389</PMID><DateCreated><Year>2015</Year><Month>05</Month><Day>20</Day></DateCreated><DateCompleted><Year>2016</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1949-2553</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>Oncotarget</Title><ISOAbbreviation>Oncotarget</ISOAbbreviation></Journal><ArticleTitle>Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.</ArticleTitle><Pagination><MedlinePgn>10473-86</MedlinePgn></Pagination><Abstract><AbstractText>The neuronal membrane protein sortilin has been reported in a few cancer cell lines, but its expression and impact in human tumors is unclear. In this study, sortilin was analyzed by immunohistochemistry in a series of 318 clinically annotated breast cancers and 53 normal breast tissues. Sortilin was detected in epithelial cells, with increased levels in cancers, as compared to normal tissues (p = 0.0088). It was found in 79% of invasive ductal carcinomas and 54% of invasive lobular carcinomas (p < 0.0001). There was an association between sortilin expression and lymph node involvement (p = 0.0093), suggesting a relationship with metastatic potential. In cell culture, sortilin levels were higher in cancer cell lines compared to non-tumorigenic breast epithelial cells and siRNA knockdown of sortilin inhibited cancer cell adhesion, while proliferation and apoptosis were not affected. Breast cancer cell migration and invasion were also inhibited by sortilin knockdown, with a decrease in focal adhesion kinase and SRC phosphorylation. In conclusion, sortilin participates in breast tumor aggressiveness and may constitute a new therapeutic target against tumor cell invasion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roselli</LastName><ForeName>Séverine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pundavela</LastName><ForeName>Jay</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demont</LastName><ForeName>Yohann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>INSERM U908, IFR-147, Universite Lille 1, Villeneuve d'Ascq 59655, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1138, Equipe 11, Centre de Recherche des Cordeliers, Paris 75006, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faulkner</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>Sheridan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attia</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health & Medicine, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Chen Chen</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xu Dong</ForeName><Initials>XD</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Marjorie M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health & Medicine, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hondermarck</LastName><ForeName>Hubert</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncotarget</MedlineTA><NlmUniqueID>101532965</NlmUniqueID><ISSNLinking>1949-2553</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033942">Adaptor Proteins, Vesicular Transport</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C104814">sortilin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2012 Dec 1;131(11):2471-7</RefSource><PMID Version="1">22581656</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurosci. 2008 Dec;9(12):899-909</RefSource><PMID Version="1">19002190</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Cell Biol. 2006 Oct;18(5):516-23</RefSource><PMID Version="1">16919435</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Invest Dermatol. 2008 Aug;128(8):2031-40</RefSource><PMID Version="1">18305571</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Genes Cancer. 2014 Jul;5(7-8):240-9</RefSource><PMID Version="1">25221642</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 May 20;30(15):1879-87</RefSource><PMID Version="1">22454417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Biochem Cell Biol. 2013 May;45(5):952-9</RefSource><PMID Version="1">23395631</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Genes Dev. 2001 Jan 1;15(1):50-65</RefSource><PMID Version="1">11156605</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2011 Oct 14;147(2):275-92</RefSource><PMID Version="1">22000009</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Mol Life Sci. 2009 Aug;66(16):2677-89</RefSource><PMID Version="1">19434368</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2014 Sep 18;513(7518):382-7</RefSource><PMID Version="1">25043054</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocrinology. 2015 Jan;156(1):58-70</RefSource><PMID Version="1">25365768</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2008 Sep 1;181(5):3027-38</RefSource><PMID Version="1">18713973</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 1999 Mar 26;274(13):8832-6</RefSource><PMID Version="1">10085125</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 2012 Apr;35(4):261-70</RefSource><PMID Version="1">22341525</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Genet. 2012 Apr;13(4):227-32</RefSource><PMID Version="1">22411467</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocrinology. 2009 Jan;150(1):509-18</RefSource><PMID Version="1">18687776</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2013 Jan 2;33(1):358-70</RefSource><PMID Version="1">23283348</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Crystallogr D Biol Crystallogr. 2014 Feb;70(Pt 2):451-60</RefSource><PMID Version="1">24531479</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(9):e25097</RefSource><PMID Version="1">21966426</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cell Sci. 2014 Sep 15;127(Pt 18):3983-97</RefSource><PMID Version="1">25037567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Invest Dermatol. 2010 Nov;130(11):2553-60</RefSource><PMID Version="1">20613775</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PeerJ. 2014 Feb 27;2:e270</RefSource><PMID Version="1">24688849</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 2014 Dec;184(12):3156-62</RefSource><PMID Version="1">25285721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Drug Discov. 2013 Jul;12(7):507-25</RefSource><PMID Version="1">23977697</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Apr 1;17(7):1741-52</RefSource><PMID Version="1">21350004</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2012 Jan 13;287(3):1923-31</RefSource><PMID Version="1">22128158</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 2011 Sep 30;667(1-3):17-22</RefSource><PMID Version="1">21664902</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 Oct 4;490(7418):61-70</RefSource><PMID Version="1">23000897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Discov. 2012 May;2(5):401-4</RefSource><PMID Version="1">22588877</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Oncol. 2010 Jun;4(3):192-208</RefSource><PMID Version="1">20452298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell Biol. 1999 Mar;19(3):1720-30</RefSource><PMID Version="1">10022859</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2011 Dec;1816(2):105-18</RefSource><PMID Version="1">21616127</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 2014 Feb;39(3):363-74</RefSource><PMID Version="1">24494677</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2004 Feb 26;427(6977):843-8</RefSource><PMID Version="1">14985763</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(3):e17911</RefSource><PMID Version="1">21445301</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2011 Mar;11(3):188-97</RefSource><PMID Version="1">21326323</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D033942" MajorTopicYN="N">Adaptor Proteins, Vesicular Transport</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4496368</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">breast cancer</Keyword><Keyword MajorTopicYN="N">cell adhesion</Keyword><Keyword MajorTopicYN="N">cell invasion</Keyword><Keyword MajorTopicYN="N">protein expression</Keyword><Keyword MajorTopicYN="N">sortilin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>02</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25871389</ArticleId><ArticleId IdType="pii">3401</ArticleId><ArticleId IdType="pmc">PMC4496368</ArticleId><ArticleId IdType="doi">10.18632/oncotarget.3401</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002E36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25871389
|texte= Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25871389" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |